RU2002126615A - Рецептуры ранолазина пролонгированного действия - Google Patents

Рецептуры ранолазина пролонгированного действия

Info

Publication number
RU2002126615A
RU2002126615A RU2002126615/14A RU2002126615A RU2002126615A RU 2002126615 A RU2002126615 A RU 2002126615A RU 2002126615/14 A RU2002126615/14 A RU 2002126615/14A RU 2002126615 A RU2002126615 A RU 2002126615A RU 2002126615 A RU2002126615 A RU 2002126615A
Authority
RU
Russia
Prior art keywords
ranolazine
patient
hours
dosage form
plasma
Prior art date
Application number
RU2002126615/14A
Other languages
English (en)
Inventor
Эндрю А. ВОЛЬФФ (US)
Эндрю А. ВОЛЬФФ
Original Assignee
СиВи ТЕРАПЬЮТИКС, ИНК. (US)
СиВи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24074628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2002126615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by СиВи ТЕРАПЬЮТИКС, ИНК. (US), СиВи ТЕРАПЬЮТИКС, ИНК. filed Critical СиВи ТЕРАПЬЮТИКС, ИНК. (US)
Publication of RU2002126615A publication Critical patent/RU2002126615A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (10)

1. Способ лечения больного, страдающего сердечнососудистым заболеванием, выбранным из аритмии, вариантной стенокардии, стенокардии напряжения и инфаркта миокарда, введением фармацевтической лекарственной формы пролонгированного действия, включающей, по меньшей мере, 50% массовых ранолазина, в форме не более двух таблеток на дозу больному для поддержания уровней ранолазина в плазме больного при минимуме 850 нг основания/мл в течение, по меньшей мере, 24 ч, где дозу вводят с частотой, выбранной из одного раза, двух и трех раз в течение 24 ч.
2. Способ по п.1, где максимальный уровень ранолазина в плазме равен примерно 4000 нг основания/мл.
3. Способ по п.1, где фармацевтическую лекарственную форму вводят больному с частотой, выбранной из одного раза и двух раз в течение 24 ч.
4. Способ по п.1, где фармацевтическую лекарственную форму вводят больному двумя дозами в течение 24 ч, где каждая доза состоит из двух таблеток.
5. Способ по п.1, где фармацевтическая лекарственная форма включает примерно между 50 и 95% массовыми ранолазина.
6. Способ по п.1, где фармацевтическая лекарственная форма включает примерно от 70 до 80% массовых ранолазина.
7. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 4:1 в течение периода 24 ч.
8. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 3:1 в течение периода 24 ч.
9. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 2:1 в течение периода 24 ч.
10. Способ по п.1, где доза включает примерно от 500 до 1500 мг ранолазина.
RU2002126615/14A 2000-03-08 2001-03-07 Рецептуры ранолазина пролонгированного действия RU2002126615A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine
US09/520,932 2000-03-08

Publications (1)

Publication Number Publication Date
RU2002126615A true RU2002126615A (ru) 2004-03-20

Family

ID=24074628

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002126615/14A RU2002126615A (ru) 2000-03-08 2001-03-07 Рецептуры ранолазина пролонгированного действия

Country Status (17)

Country Link
US (1) US6479496B1 (ru)
EP (1) EP1263439A2 (ru)
JP (2) JP4108980B2 (ru)
CN (1) CN1323664C (ru)
AU (3) AU2001240092B8 (ru)
BR (1) BR0109091A (ru)
CA (1) CA2402222C (ru)
CZ (1) CZ20022996A3 (ru)
HK (1) HK1058003A1 (ru)
HU (1) HUP0204409A3 (ru)
IL (1) IL151575A0 (ru)
MX (1) MXPA02008654A (ru)
NO (1) NO20024270L (ru)
NZ (1) NZ521292A (ru)
PL (1) PL357273A1 (ru)
RU (1) RU2002126615A (ru)
WO (1) WO2001066093A2 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP2332540A1 (en) * 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031949A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080214555A1 (en) * 2007-02-13 2008-09-04 Markus Jerling Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2152268A1 (en) * 2007-05-31 2010-02-17 CV Therapeutics Inc. Method of treating diabetes
EP2155697B1 (en) * 2007-06-13 2012-11-28 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
NO3175985T3 (ru) 2011-07-01 2018-04-28
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
JP7500379B2 (ja) 2020-09-30 2024-06-17 文化シヤッター株式会社 開閉装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Also Published As

Publication number Publication date
EP1263439A2 (en) 2002-12-11
CA2402222A1 (en) 2001-09-13
JP4108980B2 (ja) 2008-06-25
HUP0204409A3 (en) 2005-04-28
CN1323664C (zh) 2007-07-04
CA2402222C (en) 2009-11-03
MXPA02008654A (es) 2004-09-06
JP2008069159A (ja) 2008-03-27
AU2001240092B2 (en) 2004-10-14
CN1443069A (zh) 2003-09-17
JP2003525896A (ja) 2003-09-02
HUP0204409A2 (en) 2003-05-28
BR0109091A (pt) 2005-02-15
US6479496B1 (en) 2002-11-12
NZ521292A (en) 2008-07-31
AU4009201A (en) 2001-09-17
PL357273A1 (en) 2004-07-26
IL151575A0 (en) 2003-04-10
CZ20022996A3 (cs) 2003-09-17
NO20024270D0 (no) 2002-09-06
AU2001240092B8 (en) 2004-12-02
NO20024270L (no) 2002-11-06
HK1058003A1 (en) 2004-04-30
AU2008212005A1 (en) 2008-09-25
WO2001066093A3 (en) 2002-03-14
WO2001066093A2 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
RU2002126615A (ru) Рецептуры ранолазина пролонгированного действия
EP1087775B1 (en) Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
CA2433035C (en) Pharmaceutical compositions comprising amlodipine maleate
RU2001109432A (ru) Композиции с пролонгированным высвобождением ранолазина
RU2005124363A (ru) Твердые пероральные дозируемые формы валсартана
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
JP2002523370A5 (ru)
Midtbø et al. Verapamil compared with nifedipine in the treatment of essential hypertension
RU2003100507A (ru) Фармацевтические композиции
CA2456732A1 (en) Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
Brodsky et al. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study.
RU2005122403A (ru) Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
JP2006515299A5 (ru)
RU2004101231A (ru) Таблетка, содержащая цетиризин и псевдоэфедрин
RU2011131532A (ru) Способ лечения бессонницы
CA2353693A1 (en) Pharmaceutical composition containing citalopram
IL148777A (en) Mirtazepine oral oral administration unit
Tardif Clinical efficacy of ivabradine
JP2005525391A5 (ru)
Nordlander et al. Once-versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris: A randomized, double-blind, cross-over study
Maclean et al. Calcium antagonists, nitrates, and new antianginal drugs.
JP2003523385A5 (ru)
Rae et al. Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina.